FoxWayne Enterprises Acquisition in an 8-K filing said shareholders approved a merger deadline extension for up to six months beyond the current July 22 deadline. About 77% of the voted shares supported the extension. The filing did not mention redemptions, if any.
FoxWayne raised $50 million in a January 2021 IPO with plans to target a biotechnology or telemedicine company in North America.
The SPAC terminated a deal in March with Aerami Therapeutics, citing unfavorable market conditions.
FoxWayne is led by Chairman, CEO and CFO Robb Knie, who is president, CEO and Chairman of Hoth Therapeutics, a biopharmaceuticals company. Read more.
